WILMINGTON, Mass., Dec. 23, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has shipped eight QS-H150 handheld explosives trace detectors for deployment at the Media Center during the upcoming Sochi games.
The Sochi Media Center will open its doors during the Winter Games in 2014. During that time, ninety-eight events in fifteen winter sports will be held. The Sochi Media Center (inclusive of the International Broadcast Center), which will serve as the primary media venue for accredited media representatives for the Sochi games, is equipped to host multimedia events in several formats and will provide round-the-clock assistance to members of the media.
"The QS-H150 will be deployed as part of a comprehensive security package at the Sochi Media Center," stated Natalya Hall, General Manager for Russia and the CIS countries at Implant Sciences. "During the Games, the Center is expected to welcome 12,000 media representatives – including over 10,000 broadcasters representing about 100 companies from all around the world, so security is an extremely important consideration."
"Re-establishing our presence in the Russian market has been a priority for us," stated Implant Sciences' Vice President of Sales and Marketing, Darryl Jones. "This order demonstrates measurable progress against this goal. We are continuing to expand our sales presence in Russia and the CIS countries and look forward to more orders in the near future."
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution." For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation